v3.26.1
Financial Royalty Assets, net - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Nov. 30, 2023
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Jan. 31, 2025
Aug. 31, 2024
Jul. 15, 2024
Mar. 31, 2024
Intangible Asset, Finite-Lived                    
Impairment loss of financial royalty assets   $ 0 $ 0 $ 0 $ 0          
Gross carrying value   209,699   209,699   $ 222,375        
Ohtuvayre inventors                    
Intangible Asset, Finite-Lived                    
Gross carrying value             $ 1,800 $ 13,600   $ 3,800
Tolerance Therapeutics (Tzield®)                    
Intangible Asset, Finite-Lived                    
Cash payments for acquisition $ 20,000                  
Product royalty (as a percent) 1.00%                  
Deferred tax liability $ 5,500                  
Qarziba                    
Intangible Asset, Finite-Lived                    
Gross carrying value   $ 101,303   $ 101,303   $ 118,593        
Qarziba | APEIRON                    
Intangible Asset, Finite-Lived                    
Business combination, recognized identifiable assets acquired and liabilities assumed, contract assets                 $ 104,900  
InvIOs investment | APEIRON                    
Intangible Asset, Finite-Lived                    
Business combination, recognized identifiable assets acquired and liabilities assumed, contract assets                 $ 1,300